CL2017002131A1 - Formulaciones en milicápsulas que comprenden ácidos grasos libres poliinsaturados - Google Patents
Formulaciones en milicápsulas que comprenden ácidos grasos libres poliinsaturadosInfo
- Publication number
- CL2017002131A1 CL2017002131A1 CL2017002131A CL2017002131A CL2017002131A1 CL 2017002131 A1 CL2017002131 A1 CL 2017002131A1 CL 2017002131 A CL2017002131 A CL 2017002131A CL 2017002131 A CL2017002131 A CL 2017002131A CL 2017002131 A1 CL2017002131 A1 CL 2017002131A1
- Authority
- CL
- Chile
- Prior art keywords
- fatty acids
- microcapsules
- formulations
- free fatty
- pufa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>EN EL PRESENTE DOCUMENTO SE PROPORCIONAN FORMAS DE DOSIFICACIÓN EN CÁPSULAS QUE CONTIENEN COMPOSICIONES DE ÁCIDOS GRASOS POLIINSATURADOS (PUFA). EN DETERMINADAS REALIZACIONES, SE PROPORCIONAN FORMAS DE DOSIFICACIÓN UNITARIA QUE COMPRENDEN UNA SERIE DE MILICÁPSULAS QUE COMPRENDEN EN SU INTERIOR UNA COMPOSICIÓN DE PUFA ASÍ COMO SUS MÉTODOS DE USO Y FABRICACIÓN. EN DETERMINADAS REALIZACIONES, SE PROPORCIONAN EN EL PRESENTE DOCUMENTO FORMAS DE DOSIFICACIÓN EN CÁPSULAS QUE INCLUYEN UNA FORMA DE DOSIFICACIÓN UNITARIA QUE COMPRENDE UNA DIVERSIDAD DE MILICÁPSULAS QUE CONTIENEN UN ÁCIDO GRASO LIBRE POLIINSATURADO SUSTANCIALMENTE EN FORMA DE ÁCIDO LIBRE. EN ALGUNAS REALIZACIONES, LA COMPOSICIÓN DE PUFA ES EPANOVA®.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305278 | 2015-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002131A1 true CL2017002131A1 (es) | 2018-04-13 |
Family
ID=52633188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002131A CL2017002131A1 (es) | 2015-02-23 | 2017-08-21 | Formulaciones en milicápsulas que comprenden ácidos grasos libres poliinsaturados |
Country Status (16)
Country | Link |
---|---|
US (1) | US10512611B2 (es) |
EP (1) | EP3261622A4 (es) |
JP (1) | JP6469261B2 (es) |
KR (2) | KR20190090087A (es) |
CN (1) | CN107530284A (es) |
AU (1) | AU2016223109B2 (es) |
CA (1) | CA2975549C (es) |
CL (1) | CL2017002131A1 (es) |
EA (1) | EA035377B1 (es) |
HK (1) | HK1244218A1 (es) |
IL (1) | IL253697B (es) |
MA (1) | MA41611A (es) |
MX (1) | MX2017010716A (es) |
NZ (1) | NZ734149A (es) |
WO (1) | WO2016137825A1 (es) |
ZA (1) | ZA201705620B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2664429C2 (ru) | 2012-01-06 | 2018-08-17 | Омтера Фармасьютикалс, Инк. | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
EP3672585A4 (en) * | 2017-08-25 | 2021-06-16 | Struct Nutrition, LLC | COMPOSITIONS AND PROCEDURES FOR THE PREVENTION, RELIEF, AND TREATMENT OF NEUROLOGICAL INJURY AFTER HEAD TRAUMA |
CN109463762A (zh) * | 2018-12-10 | 2019-03-15 | 瞿瀚鹏 | Dha油脂组合物在软胶囊中的应用以及软胶囊及其制备方法 |
JP7315383B2 (ja) * | 2019-06-27 | 2023-07-26 | 株式会社Screenホールディングス | インクジェット用水性組成物及び固体製剤 |
KR20230151363A (ko) * | 2022-04-25 | 2023-11-01 | 유엠에스엔지니어링 주식회사 | 오메가 3 심리스 연질캡슐 제조방법 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59225115A (ja) | 1983-06-06 | 1984-12-18 | Ota Seiyaku Kk | 青魚類から得た長鎖高度不飽和脂肪酸を含有する微細カプセル |
JPS61126016A (ja) | 1984-11-22 | 1986-06-13 | Toagosei Chem Ind Co Ltd | 不飽和脂肪酸を内相物としたマイクロカプセル |
DE4201178C2 (de) * | 1992-01-17 | 1995-12-07 | Alfatec Pharma Gmbh | Verfahren zur Herstellung von Weichgelatinekapseln nach einem Tropfverfahren |
JPH0753356A (ja) | 1993-08-16 | 1995-02-28 | Morishita Jintan Kk | 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法 |
GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
JP2002527387A (ja) * | 1998-10-15 | 2002-08-27 | デーエスエム・ナムローゼ・フェンノートシャップ | Pufaサプリメント |
TW561047B (en) * | 1999-08-31 | 2003-11-11 | Chugai Pharmaceutical Co Ltd | Soft capsule formulations |
US7025984B1 (en) * | 2000-06-26 | 2006-04-11 | The Procter & Gamble Company | Compositions and methods for body weight management |
US20040217549A1 (en) * | 2003-05-01 | 2004-11-04 | Justak John F. | Hydrodynamic brush seal |
GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
US7622137B2 (en) * | 2004-05-21 | 2009-11-24 | Accu-Break Technologies, Inc. | Dosage forms contained within a capsule or sachet |
CA2613474A1 (en) * | 2005-06-20 | 2007-03-08 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
CN101287382A (zh) * | 2005-07-07 | 2008-10-15 | 加拿大海洋营养食品有限公司 | 含有输送装置的食物制品及其制造方法 |
US20070134493A1 (en) | 2005-12-08 | 2007-06-14 | Kanji Meghpara | Compositions and capsules with stable hydrophilic layers |
US20070141211A1 (en) * | 2005-12-16 | 2007-06-21 | Solae, Llc | Encapsulated Phospholipid-Stabilized Oxidizable Material |
WO2007075841A1 (en) | 2005-12-20 | 2007-07-05 | Cenestra, Llc | Omega 3 fatty acid formulations |
US20090304784A1 (en) | 2006-07-28 | 2009-12-10 | V. Mane Fils | Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component |
KR100758664B1 (ko) | 2006-08-16 | 2007-09-13 | (주)케비젠 | 불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품 |
BRPI0816507A2 (pt) * | 2007-10-17 | 2014-10-07 | Unilever Nv | "produto comestível, processo para a preparação de uma cápsula revestida e uso de um produto comestível" |
NZ587019A (en) | 2008-01-10 | 2012-07-27 | Takeda Pharmaceutical | Capsule formulation |
US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
DK2419114T4 (da) | 2009-05-01 | 2019-05-27 | Uas Laboratories Llc | Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme |
KR102354949B1 (ko) * | 2009-10-23 | 2022-01-24 | 바스프 에이에스 | 지방산 오일 혼합물의 코팅된 캡슐 및 정제 |
EP4213483A1 (en) * | 2011-05-27 | 2023-07-19 | Sun Patent Trust | Image coding method, image coding apparatus, image decoding method, image decoding apparatus, and image coding and decoding apparatus |
JP2013084557A (ja) * | 2011-07-21 | 2013-05-09 | Rohm Co Ltd | 照明装置 |
WO2013040507A1 (en) | 2011-09-15 | 2013-03-21 | Omthera Pharmaceuticals, Inc. | Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy |
US20140316003A1 (en) | 2011-10-21 | 2014-10-23 | Omthera Pharmaceuticals, Inc. | Methods and compositions for treating or preventing attention deficit hyperactivity disorder |
RU2664429C2 (ru) * | 2012-01-06 | 2018-08-17 | Омтера Фармасьютикалс, Инк. | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA |
CN104321053A (zh) * | 2012-03-30 | 2015-01-28 | 桑茨利奥&孔帕尼股份有限公司 | ω-3脂肪酸酯组合物 |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
EP3079667B1 (en) * | 2013-12-13 | 2019-06-26 | Novartis AG | Pharmaceutical dosage forms |
CN103989666A (zh) * | 2014-04-11 | 2014-08-20 | 浙江海洋学院 | n-3多不饱和脂肪酸在治疗非酒精性脂肪肝病药物中的应用 |
WO2016069446A1 (en) | 2014-10-28 | 2016-05-06 | Omthera Pharmaceuticals Inc | Methods for modulating plasma levels of lipoproteins |
WO2016073335A1 (en) | 2014-11-05 | 2016-05-12 | Omthera Pharmaceuticals Inc. | Methods of treatment |
WO2016130417A1 (en) | 2015-02-11 | 2016-08-18 | Omthera Pharmaceuticals Inc | Omega-3 fatty acid prodrug compounds and uses thereof |
-
2016
- 2016-02-18 MA MA041611A patent/MA41611A/fr unknown
- 2016-02-19 CN CN201680011129.XA patent/CN107530284A/zh active Pending
- 2016-02-19 EA EA201791766A patent/EA035377B1/ru not_active IP Right Cessation
- 2016-02-19 KR KR1020197021845A patent/KR20190090087A/ko active Application Filing
- 2016-02-19 NZ NZ734149A patent/NZ734149A/en not_active IP Right Cessation
- 2016-02-19 EP EP16756086.1A patent/EP3261622A4/en not_active Withdrawn
- 2016-02-19 MX MX2017010716A patent/MX2017010716A/es unknown
- 2016-02-19 WO PCT/US2016/018571 patent/WO2016137825A1/en active Application Filing
- 2016-02-19 US US15/552,686 patent/US10512611B2/en not_active Expired - Fee Related
- 2016-02-19 CA CA2975549A patent/CA2975549C/en not_active Expired - Fee Related
- 2016-02-19 JP JP2017562567A patent/JP6469261B2/ja not_active Expired - Fee Related
- 2016-02-19 KR KR1020177025800A patent/KR20170116153A/ko active Application Filing
- 2016-02-19 AU AU2016223109A patent/AU2016223109B2/en not_active Ceased
-
2017
- 2017-07-27 IL IL253697A patent/IL253697B/en not_active IP Right Cessation
- 2017-08-18 ZA ZA2017/05620A patent/ZA201705620B/en unknown
- 2017-08-21 CL CL2017002131A patent/CL2017002131A1/es unknown
-
2018
- 2018-03-19 HK HK18103751.3A patent/HK1244218A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016137825A8 (en) | 2017-08-31 |
CA2975549A1 (en) | 2016-09-01 |
EP3261622A1 (en) | 2018-01-03 |
WO2016137825A1 (en) | 2016-09-01 |
IL253697B (en) | 2020-08-31 |
JP2018505914A (ja) | 2018-03-01 |
JP6469261B2 (ja) | 2019-02-13 |
CN107530284A (zh) | 2018-01-02 |
EA201791766A1 (ru) | 2018-03-30 |
MA41611A (fr) | 2018-01-02 |
MX2017010716A (es) | 2018-03-16 |
EP3261622A4 (en) | 2018-12-19 |
US10512611B2 (en) | 2019-12-24 |
US20180325829A1 (en) | 2018-11-15 |
ZA201705620B (en) | 2019-06-26 |
HK1244218A1 (zh) | 2018-08-03 |
CA2975549C (en) | 2019-04-02 |
KR20190090087A (ko) | 2019-07-31 |
KR20170116153A (ko) | 2017-10-18 |
AU2016223109A1 (en) | 2017-08-17 |
AU2016223109B2 (en) | 2018-10-04 |
IL253697A0 (en) | 2017-09-28 |
EA035377B1 (ru) | 2020-06-03 |
NZ734149A (en) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002131A1 (es) | Formulaciones en milicápsulas que comprenden ácidos grasos libres poliinsaturados | |
CL2019002663A1 (es) | Producción de ácidos grasos poliinsaturados de cadena larga en células vegetales. (divisional solicitud 201702448) | |
PE20180456A1 (es) | Acidos grasos poliinsaturados de cadena muy larga a partir de aceites naturales | |
CL2014000759A1 (es) | Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. | |
AR098890A1 (es) | Proceso para obtener aceite microbiano a partir de células microbianas | |
BR112017013319A2 (pt) | processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 3 poli-insaturados. | |
BR112014031284B8 (pt) | composição, produto de cuidado pessoal, e, modificador de reologia | |
PE20141998A1 (es) | Composiciones topicas que comprenden fipronilo y permetrina y sus metodos de uso | |
BR112017022209A2 (pt) | composição aquosa que compreende éster de ácido omega- aminocarboxílico e álcool graxo e seu uso | |
CL2013003144A1 (es) | Composicion que comprende a) extracto de arroz fermentado con monascus purpureus, b) un acido graso omega, c) l-carnitina y uno o mas de los siguientes: d) al menos un policosanol, e) resveratrol, f) coenzima q10 y g) al menos una vitamina, util como anticolesterolemico y antitrigliceridemico y para aumentar el colesterol hdl. | |
SA515361092B1 (ar) | تركيبات راسكادوتريل الدهنية | |
MY195213A (en) | Release Agent Composition | |
CL2018000158A1 (es) | Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772) | |
BR112016028697A2 (pt) | artigos que fornecem fragrâncias de longa duração | |
AR099500A1 (es) | Composición para el desmucilaginado enzimático de aceite | |
CL2018003797A1 (es) | Ingredientes de pienso que comprenden células microbianas lisadas. | |
CL2016001453A1 (es) | Composiciones sintéticas de leche que comprenden ácidos grasos poliinsaturados (pufa) para promover el establecimiento saludable de la función cognitiva en infantes varones y hembras y niños y niñas. | |
IL276596A (en) | Polyunsaturated fatty acids, monoglycerides, compounds, methods and use thereof | |
CL2020001328A1 (es) | Composición en polvo que incluye gliceridos de ácidos grasos. | |
TR201901378T4 (tr) | Kakao yağı stabilize edici bitkisel katı yağ bileşimi. | |
CO7141473A2 (es) | Vehículos de liberación de composiciones pesticidas | |
BR112018006807A2 (pt) | composições de óleo e métodos de fabricação | |
ZA202107552B (en) | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof | |
MX2014009404A (es) | Composiciones de dispersion de acidos grasos saturados y trans reducidos. | |
MY201533A (en) | Palm-based wax composition |